Mary Szela T.'s Insider Trades & SAST Disclosures
Mary Szela T.'s most recent trade in TriSalus Life Sciences Inc was a trade of 21,089 Common Stock done . Disclosure was reported to the exchange on Feb. 18, 2025.
Add Superstar Alert
Share
Note
This is a custom search result for pattern Mary Szela T..To see full superstar portfolios of large investors like Warren Buffet, Elon Musk and others, click here.
Advanced/Help
"Balanced Fund": Use this format with quotation marks to find the exact phrase. The output matches
"Balanced Fund"
but not "Balanced Growth Fund"
Balanced Fund: Use this format without quotation marks to search for all funds related to the term
"Balanced Fund" The results may include
"Balanced Income Fund", "Balanced Growth Fund" and any fund name containing "Balanced Fund".
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| TriSalus Life Sciences Inc | Mary T. Szela | Director, CEO AND PRESIDENT | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 18 Feb 2025 | 21,089 | 465,348 | - | 0 | Common Stock | |
| TriSalus Life Sciences Inc | Mary T. Szela | Director, CEO AND PRESIDENT | Purchase of securities on an exchange or from another person at price $ 5.03 per share. | 29 Jan 2025 | 5,030 | 439,249 | - | 5.0 | 25,301 | Common Stock |
| TriSalus Life Sciences Inc | Mary T. Szela | Director, CEO AND PRESIDENT | Purchase of securities on an exchange or from another person at price $ 5.28 per share. | 29 Jan 2025 | 5,010 | 444,259 | - | 5.3 | 26,453 | Common Stock |
| TriSalus Life Sciences Inc | Mary T. Szela | Director, CEO AND PRESIDENT | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 27 Jan 2025 | 240,000 | 240,000 | - | - | Employee Stock Option (right to buy) | |
| TriSalus Life Sciences Inc | Mary T. Szela | Director, CEO AND PRESIDENT | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 27 Jan 2025 | 40,000 | 424,677 | - | 0 | Common Stock | |
| TriSalus Life Sciences Inc | Mary T. Szela | Director, CEO AND PRESIDENT | Purchase of securities on an exchange or from another person at price $ 5.42 per share. | 27 Jan 2025 | 4,826 | 429,503 | - | 5.4 | 26,157 | Common Stock |
| TriSalus Life Sciences Inc | Mary T. Szela | Director, CEO AND PRESIDENT | Purchase of securities on an exchange or from another person at price $ 5.12 per share. | 27 Jan 2025 | 4,716 | 434,219 | - | 5.1 | 24,146 | Common Stock |
| TriSalus Life Sciences Inc | Mary T. Szela | Director, CEO AND PRESIDENT | Purchase of securities on an exchange or from another person at price $ 5.20 per share. | 12 Sep 2024 | 7,520 | 377,382 | - | 5.2 | 39,104 | Common Stock |
| TriSalus Life Sciences Inc | Mary T. Szela | Director, CEO AND PRESIDENT | Purchase of securities on an exchange or from another person at price $ 5.00 per share. | 12 Sep 2024 | 6,000 | 384,677 | - | 5 | 30,000 | Common Stock |
| TriSalus Life Sciences Inc | Mary T. Szela | Director, CEO AND PRESIDENT | Purchase of securities on an exchange or from another person at price $ 4.83 per share. | 12 Sep 2024 | 1,295 | 378,677 | - | 4.8 | 6,255 | Common Stock |
| TriSalus Life Sciences Inc | Mary T. Szela | Director, CEO AND PRESIDENT | Purchase of securities on an exchange or from another person at price $ 4.97 per share. | 10 Sep 2024 | 5,000 | 369,862 | - | 5.0 | 24,850 | Common Stock |
| Omega Therapeutics Inc | Mary T. Szela | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 20 Jun 2024 | 25,000 | 25,000 | - | - | Stock Option (Right to Buy) | |
| Kura Oncology Inc | Mary T. Szela | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 05 Jun 2024 | 26,000 | 26,000 | - | - | Option to purchase common stock | |
| TriSalus Life Sciences Inc | Szela Mary T. | Director, CEO AND PRESIDENT | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 13 Feb 2024 | 288,750 | 288,750 | - | - | Employee Stock Option (right to buy) | |
| TriSalus Life Sciences Inc | Mary Szela T. | Director, CEO AND PRESIDENT | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 13 Feb 2024 | 84,899 | 364,862 | - | 0 | Common Stock | |
| TriSalus Life Sciences Inc | Mary T. Szela | Director, CEO and President | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 14 Aug 2023 | 172,500 | 172,500 | - | - | Employee Stock Option (right to buy) | |
| Omega Therapeutics Inc | Mary T. Szela | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 07 Jun 2023 | 18,118 | 18,118 | - | - | Stock Option (Right to Buy) | |
| Kura Oncology Inc | Mary T. Szela | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 31 May 2023 | 26,000 | 26,000 | - | - | Option to purchase common stock | |
| Kura Oncology Inc | Mary T. Szela | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 21 Jun 2022 | 23,000 | 23,000 | - | - | Option to purchase common stock | |
| Omega Therapeutics Inc | Mary T. Szela | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 08 Jun 2022 | 18,118 | 18,118 | - | - | Option (Right to Buy) | |
| Kura Oncology Inc | Mary T. Szela | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 22 Jun 2021 | 23,000 | 23,000 | - | - | Option to purchase common stock | |
| Coherus Biosciences Inc | Mary T. Szela | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 11 Jan 2021 | 20,000 | 20,000 | - | - | Stock Option (Right to Buy) | |
| Kura Oncology Inc | Mary T. Szela | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 24 Jun 2020 | 23,000 | 23,000 | - | - | Option to purchase common stock | |
| Coherus Biosciences Inc | Mary T. Szela | Director | Sale of securities on an exchange or to another person at price $ 17.58 per share. | 22 Jun 2020 | 54,997 | 0 (0%) | 0% | 17.6 | 966,759 | Common Stock, $0.0001 par value |
| Coherus Biosciences Inc | Mary T. Szela | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 10.05 per share. | 22 Jun 2020 | 20,000 | 34,997 (0%) | 0% | 10.1 | 201,000 | Common Stock, $0.0001 par value |
| Coherus Biosciences Inc | Mary T. Szela | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 12.37 per share. | 22 Jun 2020 | 20,000 | 54,997 (0%) | 0% | 12.4 | 247,400 | Common Stock, $0.0001 par value |
| Coherus Biosciences Inc | Mary T. Szela | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 22 Jun 2020 | 20,000 | 0 | - | - | Stock Option (Right to Buy) | |
| Coherus Biosciences Inc | Mary T. Szela | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 22 Jun 2020 | 20,000 | 0 | - | - | Stock Option (Right to Buy) | |
| Coherus Biosciences Inc | Mary T. Szela | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 2.50 per share. | 22 Jun 2020 | 14,997 | 14,997 (0%) | 0% | 2.5 | 37,500 | Common Stock, $0.0001 par value |
| Coherus Biosciences Inc | Mary T. Szela | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 22 Jun 2020 | 14,997 | 0 | - | - | Stock Option (Right to Buy) | |
| Alimera Sciences Inc. | Mary T. Szela | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 18 Jun 2020 | 3,333 | 3,333 | - | - | Stock Option (Right to Buy) |
*All Values are in $ Million
Client Category: Promoter/ KMP/ Director / Immediate Relatives / Employee / etc
Security Type: Share/ Warrants / Convertible Debentures
Security Type: Share/ Warrants / Convertible Debentures
Data as reported to USA Exchanges